Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
暂无分享,去创建一个
Matthew J. Frigault | P. Riedell | M. Perales | C. Turtle | M. Pasquini | C. Jacobson | F. Locke | B. Hill | S. Jaglowski | S. R. Foley | D. Landsburg | R. Tiwari | Aisha Masood | M. Majdan | Christine M. Ho | Stephen W Lim | Zhen-Huan Hu